Latest Distribution Partnerships News

Uscom Limited reported a significant revenue decline in Q4 2025 amid global market instability but is focusing on cost management and strategic partnerships to position for recovery.

Osteopore Limited reports a three-fold increase in craniofacial implant sales within a year of signing an exclusive distribution deal with Zimmer Biomet, signaling strong early traction across key global markets.

AML3D has appointed Arc Additive as its UK and European distribution partner, marking a strategic push into key manufacturing and defence markets across Europe. This move follows a successful capital raise and a contract with BAE Systems UK, underpinning AML3D’s growth ambitions.

Treasury Wine Estates has named Breakthru Beverage Group as its exclusive distributor in California, stepping in after Republic National Distributing Company exits the state. The move marks a significant shift in TWE’s US distribution strategy with financial impacts yet to be fully revealed.

OMG Group Limited has reported a remarkable 253% increase in quarterly cash receipts for Q4 FY25, driving annual revenues up 63% to $4.13 million and positioning the company for further growth in FY26.

Biome Australia Limited has reported a 69% increase in international sales revenue for FY25, reaching $1.5 million, driven by new strategic distribution agreements across Ireland, New Zealand, and Canada.

Osteopore Limited has gained Swiss market approval for its 3D-printed bioresorbable implants under the EU Medical Device Regulation, completing its European product portfolio and strengthening its partnership with Zimmer Biomet.

Tissue Repair Limited has secured major distribution partnerships in Australia, New Zealand, and Thailand for its TR Pro+® product line, marking a pivotal shift from development to commercialisation. The company is also scaling up manufacturing and advancing regulatory approvals to support its global expansion ambitions.

OMG Group Limited has reported record monthly sales of $602,000 in June 2025, driven by surging ecommerce demand and strong operational cashflow, positioning the company for continued growth in FY26.

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

xReality Group is rapidly transforming its business by focusing on its high-growth Operator XR training platform, while preparing to divest legacy entertainment assets. The company reports record revenue and expanding global reach, particularly in the US defence and law enforcement sectors.